As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Oyster Point Pharma, Inc.

Viatris is a global healthcare company that produces high-quality medicines across a range of therapeutic areas, including both noncommunicable and infectious diseases.

Viatris

Pharmaceutical Manufacturing

Oyster Point Pharma | 11,747 followers on LinkedIn. Commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases. | Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Kelly R.

COM:OYSTERPOINTRX